Lyric Pharmaceuticals announced the initial closing of a Series A financing round totaling $20.4 million.
The financing, co-led by RiverVest Venture Partners, Sante Ventures and Third Point Ventures, includes participation by Aperture Venture Partners.
Lyric is a clinical-stage pharmaceutical company co-founded in 2013 by David Wurtman, M.D., M.B.A., President & Chief Executive Officer and M. Scott Harris, M.D., Chief Medical Officer.
|Searching for more deal information? Current Partnering offers the following options:
The company is developing therapeutics for gastrointestinal indications and in-licensed its initial development candidate in September 2014.
The current financing will enable the company to perform two clinical studies, including a clinical proof of concept study, in addition to other supportive activities.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies